Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation

Modern Pathology

Volumn 23, Issue 9, 2010, Pages 1180-1190

  Ward, Stephen C ^a,b   Huang, Jiaoti ^a,c   Tickoo, Satish K ^a   Thung, Swan N ^b   Ladanyi, Marc ^a   Klimstra, David S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; CD103 ANTIGEN; CYTOKERATIN 19; CYTOKERATIN 20; CYTOKERATIN 7; EPITHELIAL CELL ADHESION MOLECULE; EPITHELIAL MEMBRANE ANTIGEN; GLYPICAN 3; MONOCLONAL ANTIBODY B.72.3;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CARCINOMA; CELL DIFFERENTIATION; CLINICAL ARTICLE; DISEASE MARKER; FEMALE; FIBROLAMELLAR CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LIVER CELL; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BILE DUCTS; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; FEMALE; HEPATOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LIVER NEOPLASMS; MALE; MIDDLE AGED; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77956295659     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.105     Document Type: Article

References (68)

1. Craig JR, Peters RL, Edmondson HA, et al. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer 1980;46:372-379.
2. Berman MM, Libbey NP, Foster JH. Hepatocellular carcinoma polygonal cell type with fibrous stroma-an atypical variant with favorable prognosis. Cancer 1980; 46:1448-1455.
3. Goodman ZD, Ishak KG, Langloss JM, et al. Combined hepatocellular- cholangiocarcinoma a histologic and immunohistochemical study. Cancer 1985;55:124-135.
4. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER and Stat Database: Incidence-SEER 17 Regs Limited-Use, November 2006 Sub (1973-2004 varying)-Linked To County Attributes-Total US, 1969-2004 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission.
5. El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology 2004;39:798-803.
6. Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology 2005;128:1655-1667.
7. Stipa F, Yoon SS, Liau KH, et al. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer 2006;106:1331-1338.
8. Berman MM, Libbey NP, Foster JH. Hepatocellular carcinoma. Polygonal cell type with fibrous stroma-an atypical variant with a favorable prognosis. Cancer 1980;46:1448-1455.
9. Nagorney DM, Adson MA, Weiland LH, et al. Fibrolamellar hepatoma. Am J Surg 1985;149:113-119.
10. Epstein BE, Pajak TF, Haulk TL, et al. Metastatic nonresectable fibrolamellar hepatoma: prognostic features and natural history. Am J Clin Oncol 1999;22:22-28.
11. El-Gazzaz G,WongW, El-Hadary MK, et al. Outcome of liver resection and transplantation for fibrolamellar hepatocellular carcinoma. Transpl Int 2000;13(Suppl 1): S406-S409.
12. Katzenstein HM, Krailo MD, Malogolowkin MH, et al. Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer 2003;97:2006-2012.
13. Kakar S, Burgart LJ, Batts KP, et al. Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis. Mod Pathol 2005;18: 1417-1423.
14. Tickoo SK, Zee SY, Obiekwe S, et al. Combined hepatocellular- cholangiocarcinoma: a histopathologic, immunohistochemical, and in situ hybridization study. Am J Surg Pathol 2002;26:989-997.
15. Stroescu C, Herlea V, Dragnea A, et al. The diagnostic value of cytokeratins and carcinoembryonic antigen immunostaining in differentiating hepatocellular carcinomas from intrahepatic cholangiocarcinomas. J Gastrointestin Liver Dis 2006;15:9-14.
16. Maeda T, Kajiyama K, Adachi E, et al. The expression of cytokeratins 7, 19, and 20 in primary and metastatic carcinomas of the liver. Mod Pathol 1996;9:901-909.
17. Lai YS, Thung SN, Gerber MA, et al. Expression of cytokeratins in normal and diseased livers and in primary liver carcinomas. Arch Pathol Lab Med 1989; 113:134-138.
18. DErrico A, Baccarini P, Fiorentino M, et al. Histogenesis of primary liver carcinomas: strengths and weaknesses of cytokeratin profile and albumin mRNA detection. Hum Pathol 1996;27:599-604.
19. Lau SK, Prakash S, Geller SA, et al. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Hum Pathol 2002;33:1175-1181.
20. Tsuji M, Kashihara T, Terada N, et al. An immunohistochemical study of hepatic atypical adenomatous hyperplasia, hepatocellular carcinoma, and cholangiocarcinoma with alpha-fetoprotein, carcinoembryonic antigen, CA19-9, epithelial membrane antigen, and cytokeratins 18 and 19. Pathol Int 1999;44:310-317.
21. Nakatsura T, Yoshitake Y, Senju S, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003;306:16-25.
22. Shafizadeh N, Ferrell LD, Kakar S. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol 2008;21:1011-1018.
23. Van Eyken P, Sciot R, Brock P, et al. Abundant expression of cytokeratin 7 in fibrolamellar carcinoma of the liver. Histopathology 1990;17:101-107.
24. Gornicka B, Ziarkiewicz-Wroblewska B, Wroblewski T, et al. Carcinoma, a fibrolamellar variant-immunohistochemical analysis of 4 cases. Hepatogastroenterology 2005;52:519-523.
25. Klein WM, Molmenti EP, Colombani PM, et al. Primary liver carcinoma arising in people younger than 30 years. Am J Clin Pathol 2005;124:491-493.
26. Collier NA, Weinbren K, Bloom SR, et al. Neurotensin secretion by fibrolamellar carcinoma of the liver. Lancet 1984;323:538-540.
27. Payne CM, Nagle RB, Paplanus SH, et al. Fibrolamellar carcinoma of liver: a primary malignant oncocytic carcinoid? Ultrastruct Pathol 1986;10:539-552.
28. Lloreta J, Vadell C, Fabregat X, et al. Fibrolamellar hepatic tumor with neurosecretory features and systemic deposition of AA amyloid. Ultrastruct Pathol 1994;18:287-292.
29. Wennerberg AE, Nalesnik MA, Coleman WB. Hepatocyte paraffin 1: a monoclonal antibody that reacts with hepatocytes and can be used for differential diagnosis of hepatic tumors. Am J Pathol 1993;143:1050-1054.
30. Chu PG, Ishizawa S, Wu E, et al. Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein. Am J Surg Pathol 2002;26:978-988.
31. Christensen WN, Boitnott JK, Kuhajda FP. Immunoperoxidase staining as a diagnostic aid for hepatocellular carcinoma. Mod Pathol 1989;2:8-12.
32. Roncalli M, Borzio M, de Biagi G, et al. Liver cell dysplasia and hepatocellular carcinoma: a histological and immunohistochemical study. Histopathology 1985;9:209-921.
33. Koelma IA, Nap M, Huitema S, et al. Hepatocellular carcinoma, adenoma, and focal nodular hyperplasia. Comparative histopathologic study with immunohistochemical parameters. Arch Pathol Lab Med 1986;110:1035-1040.
34. Machinami R, Oono Y. Carcinoembryonic antigen and lectin binding in the bile canalicular structures of hepatocellular carcinoma. Virchows Arch A Pathol Anat Histopathol 1987;412:111-118.
35. Berman MA, Burnham JA, Sheahan DG. Fibrolamellar carcinoma of the liver: an immunohistochemical study of nineteen cases and a review of the literature. Hum Pathol 1988;19:784-794.
36. Chu P, Arber DA. Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms. Frequent expression in renal cell carcinoma and endometrial stromal sarcoma. Am J Clin Pathol 2000;113:374-382.
37. Murray GI, Paterson PJ, Ewen SW, et al. In situ hybridisation of albumin mRNA in normal liver and hepatocellular carcinoma with a digoxigenin labelled oligonucleotide probe. J Clin Pathol 1992;45: 21-24.
38. Yamaguchi K, Nalesnik MA, Carr BI. In situ hybridization of albumin mRNA in normal liver and liver tumors: identification of hepatocellular origin. Virchows Arch B Cell Pathol Incl Mol Pathol 1993;64: 361-365.
39. Krishna M, Lloyd RV, Batts KP. Detection of albumin messenger RNA in hepatic and extrahepatic neoplasms. A marker of hepatocellular differentiation. Am J Surg Pathol 1997;21:147-152.
40. Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125:89-97.
41. Yamauchi N, Watanabe A, Hishinuma M, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 2005;18:1591-1598.
42. Wang XY, Degos F, Dubois S, et al. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol 2006;37:1435-1441.
43. Libbrecht L, Severi T, Cassiman D, et al. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol 2006;30:1405-1411.
44. Durnez A, Verslype C, Nevens F, et al. The clinicopathological and prognostic relevance of cytokeratin7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 2006; 49:138-151.
45. Yang XR, Xu Y, Shi GM, et al. Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in HCC patients after curative resection. Clin Cancer Res 2008;14:3850-3859.
46. Zhuang PY, Zhang JB, Zhu XD, et al. Two pathologic types of hepatocellular carcinoma with lymphnode metastasis with distinct prognosis on the basis of CK19 expression in tumor. Cancer 2008;112:2740-2748.
47. Trzpis M, McLaughlin PMJ, de Leij LM, et al. Epithelial cell adhesion molecule. More than a carcinoma marker and adhesion molecule. Am J Pathol 2007;171:386-395.
48. Yamashita T, Forgues M, Wang W, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic types of HCC. Cancer Res 2008;68:1451-1461.
49. Ruck P, Xiao JC, Pietsch T, et al. Hepatic stem-like cells in hepatoblastoma: expression of cytokeratin 7, albumin and oval cell associated antigens detected by OV-1 and OV-6. Histopathology 1997;31:324-329.
50. Ruck P, Wichert G, Handgretinger R, et al. Ep-CAM in malignant liver tumours. J Pathol 2000;191: 102-103.
51. Ward SC, Thung SN, Lim KH, et al. Hepatic progenitor cells in liver cancers from Asian children. Liver Int 2010;30:102-111.
52. Katoonizadeh A, Nevens F, Verslype C, et al. Liver regeneration in acute severe liver impairment: a clinicopathological correlation study. Liver Int 2006; 26:1225-1233.
53. Tan J, Hytiroglou P, Wieczorek R, et al. Immunohistochemical evidence for hepatic progenitor cells in liver diseases. Liver 2002;22:365-373.
54. Leong AS, Sormunen RT, Tsui WM, et al. Hep Par 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma, combined tumours and metastatic carcinoma. Histopathology 1998;33:318-324.
55. Saleh HA, Aulicino M, Zaidi SY, et al. Discriminating hepatocellular carcinoma from metastatic carcinoma on fine-needle aspiration biopsy of the liver: the utility of immunocytochemical panel. Diagn Cytopathol 2009;37:184-190.
56. Hsia CC, Evarts RP, Nakatsukasa H, et al. Occurrence of oval-type cells in hepatitis B virus-associated human hepatocarcinogenesis. Hepatology 1992;16:1327-1333.
57. Roskams T, De Vos R, Desmet V. Undifferentiated progenitor cells in focal nodular hyperplasia of the liver. Histopathology 1996;28:291-299.
58. Libbrecht L, Desmet V, Van Damme B, et al. The immunohistochemical phenotype of dysplastic foci in human liver: correlation with putative progenitor cells. J Hepatol 2000;33:76-84.
59. Le Bail B, Faouzi S, Boussarie L, et al. Extracellular matrix composition and integrin expression in early hepatocarcinogenesis in human cirrhotic liver. J Pathol 1997;181:330-337.
60. Libbrecht L, De Vos R, Cassiman D, et al. Hepatic progenitor cells in hepatocellular adenomas. Am J Surg Pathol 2001;25:1388-1396.
61. Roskams T, van den Oord JJ, De Vos R, et al. Neuroendocrine features of reactive bile ductules in cholestatic liver disease. Am J Pathol 1990;137: 1019-1025.
62. Wang JH, Dhillon AP, Sankey EA, et al. Neuroendocrine0 differentiation in primary neoplasms of the liver. J Pathol 1991;163:61-67.
63. Zhao M, Laissue JA, Zimmermann A. Neuroendocrine differentiation in hepatocellular carcinomas (HCCs): immunohistochemical reactivity is related to distinct tumor cell types, but not to tumor grade. Histol Histopathol 1993;8:617-626.
64. Stevens WR, Johnson CD, Stephens DH, et al. Fibrolamellar hepatocellular carcinoma: stage at presentation and results of aggressive surgical management. AJR Am J Roentgenol 1995;164:1153-1158.
65. Vauthey JN, Klimstra D, Franceschi D, et al. Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma. Am J Surg 1995;169:28-34.
66. Choi SB, Kim KS, Choi JY, et al. The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol 2009;16:3048-3056.
67. Nakagawa T, Kamiyama T, Kurauchi N, et al. Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma. World J Surg 2005;29:728-733.
68. Davies JQ, de la Hall PM, Kaschula RO, et al. Hepatoblastoma-evolution of management and outcome and significance of histology of the resected tumor. A 31-year experience with 40 cases. J Pediatr Surg 2004;39:1321-1327.